title: Partial amino acid sequence of purified von Willebrand factor-cleaving protease.
abstract: von Willebrand factor-cleaving protease (vWF-cp) is responsible for the continuous degradation of plasma vWF multimers released from endothelial cells. It is deficient in patients with thrombotic thrombocytopenic purpura, who show unusually large vWF multimers in plasma. Purified vWF-cp may be useful for replacement in these patients, who are now treated by plasma therapy. In this study, vWF-cp was purified from normal human plasma by affinity chromatography on the IgG fraction from a patient with autoantibodies to vWF-cp and by a series of further chromatographic procedures, including affinity chromatography on Protein G, Ig-TheraSorb, lentil lectin, and heparin. Four single-chain protein bands, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions, showed M(r) of 150, 140, 130, and 110 kd and were found to share the same N-terminal amino acid sequence, suggesting that they were derived from the same polypeptide chain that had been partially degraded at the carboxy-terminal end. A hydrophobic sequence (Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val-Gly) of the first 15 residues was established. The protease migrates in gel filtration as a high-molecular-weight complex with clusterin, a 70-kd protein with chaperonelike activity. vWF-cp bound to clusterin is dissociated by the use of concentrated chaotropic salts. vWF-cp in normal human plasma or serum is not associated with clusterin, suggesting that the observed complex is due to vWF-cp denaturation during the purification procedure. Activity of vWF-cp is unusually stable during incubation at 37 degrees C; its in vitro half-life in citrated human plasma, heparin plasma, or serum is longer than 1 week. There was even a temporary increase in protease activity during the first 3 days of incubation.
authors.affiliation: Central Hematology Laboratory, University Hospital, Inselspital, Bern, Switzerland.
authors.forename: H E
authors.initials: HE
authors.lastname: Gerritsen
authors.forename: R
authors.initials: R
authors.lastname: Robles
authors.forename: B
authors.initials: B
authors.lastname: Lämmle
authors.forename: M
authors.initials: M
authors.lastname: Furlan
mesh_terms: D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000276:immunology; D002846:Chromatography, Affinity; D051152:Clusterin; D004795:Enzyme Stability; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D008666:Metalloendopeptidases / Q000737:chemistry* / Q000302:isolation & purification* / Q000378:metabolism; D018832:Molecular Chaperones / Q000276:immunology; D008969:Molecular Sequence Data; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; C495242:CLU protein, human; D051152:Clusterin; D006023:Glycoproteins; D018832:Molecular Chaperones; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human